All told, it looks like LGND is the best call-option-like play on MK-8931.
Yes, it sounds like it. I am also searching for any other companies that are targeting soluble amyloid beta, be it via BACE or another approach. I found a private company: http://www.acumenpharm.com . But, if anyone knows of any other public companies pursuing this approach, I'd be curious.
Market Data 
Markets 
AI
